Publication | Closed Access

Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial

Lymphoid NeoplasiaSurgical OncologyIndolent Non-hodgkinMedicinePathologyMaintenance TherapyInterim Follow-upImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyRadiation Oncology